KRAS P.G12D

Clinical trials for KRAS P.G12D explained in plain language.

Never miss a new study

Get alerted when new KRAS P.G12D trials appear

Sign up with your email to follow new studies for KRAS P.G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

First patients sought for new targeted cancer pill trial

Disease control Not yet recruiting

This is the first study in people to test a new oral drug called D3S-003. It is for adults with advanced solid tumors that have a specific genetic change called KRAS G12D and have stopped responding to standard treatments. The main goals are to find a safe dose, see how the body …

Matched conditions: KRAS P.G12D

Phase: PHASE1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control

Last updated Mar 18, 2026 14:41 UTC

KRAS P.G12D

Get alerted when new KRAS P.G12D trials appear

First patients sought for new targeted cancer pill trial